These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8665772)

  • 1. Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs.
    Supaporn T; Wennberg PW; Wei CM; Kinoshita M; Matsuda Y; Burnett JC
    Clin Sci (Lond); 1996 May; 90(5):357-62. PubMed ID: 8665772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems.
    Wright RS; Wei CM; Kim CH; Kinoshita M; Matsuda Y; Aarhus LL; Burnett JC; Miller WL
    J Am Coll Cardiol; 1996 Oct; 28(4):1031-8. PubMed ID: 8837586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors.
    Wada A; Tsutamoto T; Matsuda Y; Kinoshita M
    Circulation; 1994 May; 89(5):2232-40. PubMed ID: 7910118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure.
    Stevens TL; Rasmussen TE; Wei CM; Kinoshita M; Matsuda Y; Burnett JC
    J Card Fail; 1996 Jun; 2(2):119-25. PubMed ID: 8798113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart.
    Yamamoto K; Burnett JC; Redfield MM
    Am J Physiol; 1997 Nov; 273(5):H2406-14. PubMed ID: 9374778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism.
    Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC
    Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of endogenous atrial natriuretic peptide in DOCA-salt hypertensive rats. Effects of a novel nonpeptide antagonist for atrial natriuretic peptide receptor.
    Hirata Y; Matsuoka H; Suzuki E; Hayakawa H; Sugimoto T; Matsuda Y; Morishita Y; Kangawa K; Minamino N; Matsuo H
    Circulation; 1993 Feb; 87(2):554-61. PubMed ID: 8381060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of endogenous atrial natriuretic peptide in chronic anemia in the ovine fetus: effects of a non-peptide antagonist for atrial natriuretic peptide receptor.
    Silberbach M; Woods LL; Hohimer AR; Shiota T; Matsuda Y; Davis LE
    Pediatr Res; 1995 Nov; 38(5):722-8. PubMed ID: 8552440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of exogenous and endogenous atrial natriuretic peptide by a receptor inhibitor.
    Stevens TL; Wei CM; Aahrus LL; Heublein DM; Kinoshita M; Matsuda Y; Burnett JC
    Hypertension; 1994 May; 23(5):613-8. PubMed ID: 8175170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial natriuretic peptides in canine hypoxic pulmonary vasoconstriction.
    Vachiery JL; Lejeune P; Hallemans R; Brimioulle S; Debiève MF; Abramow M; Naeije R
    Cardiovasc Res; 1990 May; 24(5):352-7. PubMed ID: 2164881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure.
    Tsutamoto T; Kanamori T; Wada A; Kinoshita M
    J Am Coll Cardiol; 1992 Sep; 20(3):541-6. PubMed ID: 1324959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin. I. Selective inhibition of the actions of natriuretic peptides in anesthetized rats.
    Sano T; Morishita Y; Matsuda Y; Yamada K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):825-31. PubMed ID: 1346647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo vasodilatory action of atrial natriuretic peptides in canine coronary circulation.
    Liu Q; Nakae I; Tsutamoto T; Takaoka A; Kinoshita M
    Jpn Circ J; 1996 May; 60(5):300-10. PubMed ID: 8803724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling.
    Madhani M; Scotland RS; MacAllister RJ; Hobbs AJ
    Br J Pharmacol; 2003 Aug; 139(7):1289-96. PubMed ID: 12890708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term and long-term inhibition of endogenous atrial natriuretic peptide in dogs with early-stage heart failure.
    Fukai D; Wada A; Tsutamoto T; Kinoshita M
    Jpn Circ J; 1998 Aug; 62(8):604-10. PubMed ID: 9741739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway.
    Yokota N; Bruneau BG; Kuroski de Bold ML; de Bold AJ
    J Clin Invest; 1994 Nov; 94(5):1938-46. PubMed ID: 7962539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors.
    Imura R; Sano T; Goto J; Yamada K; Matsuda Y
    Mol Pharmacol; 1992 Dec; 42(6):982-90. PubMed ID: 1362244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial natriuretic peptide (ANP) inhibits its own secretion via ANP(A) receptors: altered effect in experimental hypertension.
    Leskinen H; Vuolteenaho O; Toth M; Ruskoaho H
    Endocrinology; 1997 May; 138(5):1893-902. PubMed ID: 9112384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure.
    Zhang PL; Mackenzie HS; Totsune K; Troy JL; Brenner BM
    Circ Res; 1995 Dec; 77(6):1240-5. PubMed ID: 7586237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway.
    Yamamoto T; Wada A; Tsutamoto T; Ohnishi M; Horie M
    J Cardiovasc Pharmacol; 2004 Nov; 44(5):596-600. PubMed ID: 15505498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.